Stockscreener 앱 받기
12.50
5.31%
0.63
Intellia Therapeutics Inc 주식(NTLA)의 최신 뉴스
Cathie Wood’s ARK Made Just One Buy Last Session — And It’s A Biotech Stock Up Nearly 30% YTD - Stocktwits
Intellia Therapeutics (NTLA) Stock: Cathie Wood’s ARK Buys Third Day Running - Blockonomi
Sumitomo Mitsui Trust Group Inc. Sells 316,409 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat
Intellia Therapeutics (NTLA) Stock: Cathie Wood Continues Three-Day Buying Streak - CoinCentral
Cathie Wood’s ARK made just one buy last session — and it’s a biotech stock up nearly 30% YTD - MSN
Cathie Wood’s ARK adds to Intellia stock holdings on January 15 By Investing.com - Investing.com South Africa
ARK Investment Increases Stake in Intellia Therapeutics (NTLA) - GuruFocus
Cathie Wood’s ARK adds to Intellia stock holdings on January 15 - Investing.com India
ARK Invest Acquires 56,769 Shares of Intellia, Stock Rises 2% - Intellectia AI
JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death - Yahoo Finance
Intellia Therapeutics (NTLA) Is Up 20.7% After FDA Halts MAGNITUDE ATTR-CM Trial Over Safety EventHas The Bull Case Changed? - Sahm
Assessing Intellia Therapeutics (NTLA) Valuation After FDA Clinical Hold On Lead Gene Editing Trial - Sahm
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Best Nasdaq Stocks Clinical Innovation - Kalkine Media
Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 200-Day Moving Average - Yahoo Finance
SG Americas Securities LLC Acquires 92,485 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat
cathie wood’s ARK stock buys INTELLIA, continues trend By Investing.com - Investing.com Nigeria
cathie wood’s ARK stock buys INTELLIA, continues trend - Investing.com
Intellia Therapeutics (NASDAQ:NTLA) Trading Up 6.9%Still a Buy? - MarketBeat
cathie wood’s ARK stock trades highlight intellia, personalis buys By Investing.com - Investing.com Australia
cathie wood’s ARK stock trades highlight intellia, personalis buys - Investing.com
Analysts Are Bullish on Top Healthcare Stocks: Intellia Therapeutics (NTLA), Roche Holding AG (RHHVF) - The Globe and Mail
Intellia CEO Sells $314K in Stock While Holding Over 1 Million Shares - sharewise.com
Fred Cohen Buys 303% More Intellia Therapeutics Shares - Yahoo Finance
Intellia Therapeutics (NASDAQ:NTLA) Upgraded at Wall Street Zen - MarketBeat
Cathie Wood’s ARK ETF Buys Intellia, Personalised Stock; Sells Illumina By Investing.com - Investing.com Canada
Cathie Wood’s ARK ETF Buys Intellia, Personalised Stock; Sells Illumina - Investing.com
Intellia Updates Investors on Nex-Z Trial Safety Hold - TipRanks
Intellia Therapeutics, Inc. Updates on Clinical Trials and Regulatory Plans - TradingView — Track All Markets
Why Intellia Therapeutics Inc. (38I) stock fits value portfoliosMarket Movement Recap & AI Optimized Trade Strategies - ulpravda.ru
CEO Change: Is Intellia Therapeutics Inc. stock a defensive play in 2025Wall Street Watch & Safe Capital Allocation Plans - ulpravda.ru
How Intellia Therapeutics Inc. stock benefits from global expansion2025 Earnings Surprises & Safe Swing Trade Setups - ulpravda.ru
Buyback Watch: Can Intellia Therapeutics Inc. stock beat market expectations this quarterWeekly Trend Report & Free Long-Term Investment Growth Plans - ulpravda.ru
Intellia Therapeutics (NASDAQ:NTLA) Shares Gap UpTime to Buy? - MarketBeat
Gene Editing Tools Market to Reach US$ 1,700.05 million by 2033 | - openPR.com
Insider Buying: Fred Cohen Acquires 150,000 Shares of Intellia T - GuruFocus
Intellia Therapeutics (NASDAQ:NTLA) CEO John Leonard Sells 34,146 Shares of Stock - MarketBeat
Intellia Therapeutics Insider Sold Shares Worth $314,485, According to a Recent SEC Filing - marketscreener.com
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Intellia Therapeutics
Intellia Therapeutics prepares for JPM Healthcare Conference presentation - Traders Union
44th Annual J.P. Morgan Healthcare Conference - Intellia Therapeutics
Gene editing firm Intellia to share CRISPR work at major health event - Stock Titan
What analysts say about Intellia Therapeutics Inc 38I stockUtilities Sector Analysis & Identify Ideal Buy Points With Precision - earlytimes.in
Why Intellia Therapeutics (NTLA) Is Down After FDA Halts Key CRISPR Trial Over Safety Concerns – And What's Next - Sahm
BofA Adjusts Price Target on Intellia Therapeutics to $12 From $14, Maintains Neutral Rating - marketscreener.com
Intellia Stock Declines Around 55% in 3 Months: Here's Why - Finviz
Intellia Therapeutics reports inducement grants - Medical Buyer
We Think Intellia Therapeutics (NASDAQ:NTLA) Needs To Drive Business Growth Carefully - Yahoo Finance
Intellia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aug Big Picture: Can Intellia Therapeutics Inc stock beat analyst upgradesJuly 2025 Momentum & Daily Technical Stock Forecast Reports - moha.gov.vn
Trading the Move, Not the Narrative: (NTLA) Edition - Stock Traders Daily
4.73%
0.92%
자본화:
|
볼륨(24시간):